Guinea-Bissau has halted a controversial US-backed vaccine trial involving thousands of newborn babies, with the researchers acknowledging that the study will not proceed after authorities seized hepatitis B vaccines from a research facility in the West African country.
The decision brings a turbulent chapter in the country’s public-health research to an abrupt end. What began as a proposed scientific investigation into childhood vaccination has become an international controversy over medical ethics, government authority and the risks of conducting research among vulnerable populations.
Police seize vaccines in Bissau
The country’s judicial police raided the Bandim Health Project in the capital, Bissau, on October 19, confiscating a consignment of hepatitis B vaccines intended for children.
According to the Guinea-Bissau News Agency’s account of the operation, investigators are examining the circumstances surrounding the vaccines and whether any laws were broken.
Police were careful to stress that the seizure was part of an investigation, not evidence that the vaccines themselves were dangerous or ineffective.
The distinction is important. At the centre of the controversy is not the safety of hepatitis B vaccination, which has been established through decades of use, but whether the proposed research was scientifically justified and ethically acceptable.
Researchers confirm trial will not proceed
The clearest indication of the project’s fate came on October 21.
Frederik Schaltz-Buchholzer, one of the Danish researchers leading the study, acknowledged that the trial could no longer proceed because the necessary government approval had not been secured.
As UK’s The Guardian newspaper reported on Wednesday, his statement followed repeated objections from Guinea-Bissau’s health authorities.
Health Minister Quinhin Nantote had already rejected suggestions that the government had authorised the controversial project.
The researchers had previously maintained that they possessed approval from a national ethics committee, but that position did not resolve the government’s objections.
The dispute exposed an important question: who ultimately has the authority to approve sensitive medical research involving children, particularly when the project is backed by foreign institutions?
Why the WHO opposed the study
The proposed trial would have enrolled approximately 14,000 newborns, randomly dividing them into two groups.
Half would receive a hepatitis B vaccine shortly after birth. The others would follow Guinea-Bissau’s existing immunisation schedule, receiving their first hepatitis B doses several weeks later.
The researchers argued that this arrangement would not deprive children of vaccinations currently available under national policy.
But the World Health Organisation (WHO) strongly disagreed with the ethical basis of the experiment.
In its official assessment of the proposed Guinea-Bissau trial, the WHO warned that withholding an already proven intervention from some participants could expose newborns to preventable harm.
The agency says vaccination at birth prevents between 70 and 95 percent of hepatitis B transmission from mother to child.
Those figures carry particular weight in Guinea-Bissau, where more than 12 percent of adults are estimated to have chronic hepatitis B.
Around two percent of children under five are also believed to be infected.
For babies who contract the virus during childbirth, the consequences can last a lifetime. Chronic hepatitis B increases the risk of serious liver disease, including cirrhosis and cancer.
US funding puts research under scrutiny
The project was due to receive $1.6m from the US Centers for Disease Control and Prevention, alongside another $1.6m from private backers.
Researchers associated with the University of Southern Denmark wanted to investigate whether administering hepatitis B vaccination alongside other childhood vaccines could have broader effects on infant health.
They have insisted that the study was not designed to challenge the vaccine’s established effectiveness against hepatitis B.
In their formal response to the WHO’s criticism, the research team argued that every participating child would receive the vaccines required under Guinea-Bissau’s existing schedule.
They also said the trial could help inform vaccination policies in other African countries.
Critics were unconvinced.
Their concern was that babies could be denied an internationally recommended birth dose simply to answer a research question whose scientific justification remained disputed.
The controversy also attracted attention because US Health Secretary Robert F Kennedy Jr has publicly supported the Danish researchers, whose work on vaccines has faced scrutiny from other scientists.
African oversight comes into focus
Beyond the scientific disagreement, the episode has highlighted the importance of African governments retaining meaningful control over research conducted within their borders.
Guinea-Bissau has a long history of collaboration with international health researchers. Such partnerships have contributed to scientific knowledge and can bring resources to health systems operating under considerable financial pressure.
But cooperation also depends on trust.
When research involves newborn babies, that trust must extend to parents, medical professionals and the national institutions responsible for protecting participants.
A June analysis in The Lancet Global Health examined the trial’s ethical shortcomings, including concerns about maternal screening, scientific methodology and research oversight.
Its findings reinforced the need for international research partnerships to meet rigorous ethical standards, particularly where poverty and limited healthcare access could influence participation.
Protecting newborns remains the priority
With the trial halted, attention now turns to what happens to the confiscated vaccines and whether Guinea-Bissau can accelerate protection against hepatitis B.
The government has already committed to introducing routine hepatitis B vaccination at birth, with nationwide implementation planned by 2028.
Health experts argue that bringing forward access to the vaccine would offer a more immediate benefit to children than pursuing the disputed experiment.
The WHO continues to recommend administering the first dose within 24 hours of birth, followed by further doses under national immunisation schedules.
The unanswered question is whether the funding and vaccines intended for the abandoned trial can now help expand access to that protection.
For Guinea-Bissau, the controversy has demonstrated that international research partnerships cannot succeed on scientific ambition alone.
They require public confidence, credible oversight and the consent of the authorities responsible for protecting participants.
And for the thousands of babies whose health was at the centre of this dispute, the most pressing issue is no longer whether the experiment should proceed, but how quickly they can receive protection against a disease that is already preventable.
